title: Clinical significance of serum CYFRA 21-1 in gastric cancer.
abstract: We studied the clinical significance of the soluble cytokeratin 19 fragment detected with monoclonal antibody CYFRA 21-1 in the sera of patients with histologically proven gastric cancer. Sera of 110 patients with gastric cancer were analysed for CYFRA 21-1 levels by a two-step sandwich enzyme immunoassay. There were no significant differences between CYFRA 21-1 levels and the histotype, depth of invasion or vessel invasion. However, CYFRA 21-1 was significantly higher in the presence of peritoneal metastases, liver metastases and extensive nodal involvement. When the positive cut-off value was defined as 5 ng ml-1, the CYFRA 21-1 in the stage IV and recurrent cases was 55.6% and 66.7%, respectively, which was as high as carcinoembryonic antigen (CEA) and greater than carbohydrate antigen 19-9 (CA 19-9). The positivities in stage I/II and III were zero and 5.9%, respectively, and false-positive rate in 76 patients with benign gastrointestinal disorders was 2.6%. There appeared to be no correlation between CYFRA 21-1 and CEA or CA 19-9. The patients with above 5 n ml-1 of CYFRA 21-1 had a significantly poorer prognosis. Multivariate analysis indicated that CYFRA 21-1 was an independent prognostic factor, while CEA and CA 19-9 failed to be of prognostic value. In conclusion, CYFRA 21-1 is a reliable tumour marker for gastic cancer in predicting very advanced cases, recurrence of the disease and overall poor prognosis.
authors.affiliation: First Department of Surgery, Osaka City University Medical School, Japan.
authors.forename: B
authors.initials: B
authors.lastname: Nakata
authors.forename: Y S
authors.initials: YS
authors.lastname: Chung
authors.forename: Y
authors.initials: Y
authors.lastname: Kato
authors.forename: M
authors.initials: M
authors.lastname: Ogawa
authors.forename: Y
authors.initials: Y
authors.lastname: Ogawa
authors.forename: A
authors.initials: A
authors.lastname: Inui
authors.forename: K
authors.initials: K
authors.lastname: Maeda
authors.forename: T
authors.initials: T
authors.lastname: Sawada
authors.forename: M
authors.initials: M
authors.lastname: Sowa
mesh_terms: D000911:Antibodies, Monoclonal / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D006801:Humans; D007124:Immunoenzyme Techniques; D007633:Keratins / Q000097:blood*; D009364:Neoplasm Recurrence, Local / Q000097:blood; D009367:Neoplasm Staging; D010446:Peptide Fragments / Q000097:blood*; D011379:Prognosis; D013274:Stomach Neoplasms / Q000097:blood*
chemical_list: D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D010446:Peptide Fragments; D007633:Keratins